Immix Biopharma, Inc. (IMMX)

USD 2.1

(-8.3%)

Market Cap (In USD)

57.76 Million

Revenue (In USD)

-

Net Income (In USD)

-15.42 Million

Avg. Volume

143.07 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.26-7.5
PE
-
EPS
-
Beta Value
0.104
ISIN
US45258H1068
CUSIP
45258H106
CIK
1873835
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
Employee Count
-
Website
https://www.immixbio.com
Ipo Date
2021-12-16
Details
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.